Health Canada to review Arcutis' roflumilast NDS for plaque psoriasis

Health Canada accepted to review Arcutis Biotherapeutics’ NDS for roflumilast cream 0.3% to treat plaque psoriasis in adults and adolescents.

Related Keywords

Canada ,Canadians ,Arcutis Roflumilast ,Arcutis Biotherapeutics ,Frank Watanabe ,Us Food Drug Administration ,Health Canada ,Gxp Audit Provider For Pharmaceutical Companies ,Investigator Global Assessment ,Intertriginous Psoriasis Area Severity ,Drug Administration ,Peptide Synthesis ,Peptide Libraries ,Preference Management Solution ,